Commerzbank reiterated their buy rating on shares of Qiagen (NASDAQ:QGEN) in a report released on Tuesday morning.

Other equities analysts have also recently issued research reports about the stock. J P Morgan Chase & Co restated a neutral rating on shares of Qiagen in a research report on Tuesday, November 7th. Cowen restated a hold rating and set a $33.00 target price on shares of Qiagen in a research report on Monday, August 14th. Zacks Investment Research cut shares of Qiagen from a hold rating to a sell rating in a research report on Monday. TheStreet upgraded shares of Qiagen from a c+ rating to a b+ rating in a research report on Tuesday, November 7th. Finally, Deutsche Bank restated a buy rating on shares of Qiagen in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Qiagen currently has an average rating of Hold and an average target price of $34.06.

Shares of Qiagen (QGEN) traded up $0.41 during midday trading on Tuesday, hitting $31.67. 753,800 shares of the company traded hands, compared to its average volume of 956,815. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. Qiagen has a 12-month low of $27.51 and a 12-month high of $36.34. The firm has a market capitalization of $7,116.66, a PE ratio of 25.42, a price-to-earnings-growth ratio of 1.91 and a beta of 1.10.

Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. During the same quarter last year, the business earned $0.29 earnings per share. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. research analysts forecast that Qiagen will post 1.25 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new stake in Qiagen during the third quarter worth approximately $753,000. Airain ltd purchased a new stake in Qiagen during the second quarter worth approximately $1,390,000. Assenagon Asset Management S.A. purchased a new stake in Qiagen during the third quarter worth approximately $10,110,000. Neuberger Berman Group LLC grew its stake in Qiagen by 22.6% during the second quarter. Neuberger Berman Group LLC now owns 1,349,457 shares of the company’s stock worth $45,247,000 after buying an additional 249,176 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in Qiagen during the second quarter worth approximately $5,195,000. Hedge funds and other institutional investors own 62.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/qiagen-qgen-given-buy-rating-at-commerzbank/1761508.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.